TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23154219

Group type: EXPERIMENTAL
Intervention: Cooking television program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nature television program
Number of subjects: 80
Study: 22014247

Group type: EXPERIMENTAL
Intervention: Pocket guide
Number of subjects: 115

Group type: COMPARATOR
Intervention: UpToDate
Number of subjects: 115
Study: 19080457

Group type: EXPERIMENTAL
Intervention: Multi-point puncture group
Number of subjects: 94

Group type: COMPARATOR
Intervention: One-point puncture group
Number of subjects: 94
Study: 16825000

Group type: EXPERIMENTAL
Intervention: Mild TR
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Moderate TR
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Severe TR
Number of subjects: 225
Study: 16167722

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (250 mcg every four hours)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intracervical Foley's catheter
Number of subjects: 121
Study: 10708161

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.15 mg rhGH/kg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total parenteral nutrition alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal postabsorptive controls
Number of subjects: 28
Study: 9396090

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate ointment (2%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotinic acid ointment (10%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 10
Study: 8135384

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg of clonidine (CG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Epinephrine 1/200,000 (EG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No additional medication (BG)
Number of subjects: 45
Study: 2680795

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 240 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) after an additional course
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) and Placebo
Number of subjects: 50
Study: 797554

Group type: EXPERIMENTAL
Intervention: Desonide cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluocinonide cream
Number of subjects: 100
Study: 31053405

Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m2) and Doxorubicin (45 mg/m2)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2), Doxorubicin (45 mg/m2), and Paclitaxel (160 mg/m2)
Number of subjects: 311
Study: 27931762

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 40
Study: 25080875

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (combining pharmacological treatment, education, physical therapy, and cognitive behavioural therapy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional pharmacologic treatment
Number of subjects: 130
Study: 25458645

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CR) including exercise training (ET) for 6 months, biweekly sessions, endurance and low-intensity resistance training.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC) with management according to current heart failure guidelines.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CR) including exercise training (ET) for 6 months.
Number of subjects: 0
Study: 22973911

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasogastric tube (NGT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 0

Group type: COMPARATOR
Intervention: NGT
Number of subjects: 0
Study: 19201326

Group type: EXPERIMENTAL
Intervention: HFLCS (Pro Seal, Reliance Orthodontic Products, Itasca, Ill) applied to etched enamel surfaces before bonding.
Number of subjects: 80

Group type: COMPARATOR
Intervention: No HFLCS applied (control group) with brackets bonded directly to etched enamel surfaces.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metal brackets bonded with RMGIC.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ceramic brackets bonded with RMGIC.
Number of subjects: 80
Study: 17542406

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted (LD) isothermic blood cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isothermic blood cardioplegia (Control)
Number of subjects: 0
Study: 15198764

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted strategy (audit and feedback, educational meetings, structured case records, patient information booklet)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Printed guideline summaries
Number of subjects: 26
Study: 11487606

Group type: EXPERIMENTAL
Intervention: Skilled finger movement exercise
Number of subjects: 14
Study: 9183581

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris patients
Number of subjects: 767

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Female patients with stable angina pectoris
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Male patients with stable angina pectoris
Number of subjects: 767
Study: 1397477

Group type: EXPERIMENTAL
Intervention: Bezafibrate (BZF) 400 mg/day for one month
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acipimox (APX) 500 mg/day for one month
Number of subjects: 16
Study: 3554901

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg nocte)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg nocte)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30154027

Group type: EXPERIMENTAL
Intervention: MONEO platform (smartphone-based), cognitive training twice a week, assessed monthly via teleconference
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo group (limited functionality, cognitive training every 6 months)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: MONEO platform (study group)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 290
Study: 29864505

Group type: EXPERIMENTAL
Intervention: Inorganic NO3- supplementation (beetroot powder; 250 mg of NO3- and 20 mg of NO2-) for four weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (beetroot powder devoid of NO3-/NO2-) for four weeks
Number of subjects: 13
Study: 26670174

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Angio-guided PCI
Number of subjects: 1157
Study: 24769563

Group type: EXPERIMENTAL
Intervention: Triclosan mouthrinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Essential oils in ethanolic solution mouthrinse
Number of subjects: 80
Study: 23232161

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training combined with Conventional Therapy (CT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (VR + CT and CT)
Number of subjects: 26
Study: 19937975

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 326

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 326
Study: 17491269

Group type: EXPERIMENTAL
Intervention: Longqingpian combined with Levofloxacin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Puleanpian combined with Levofloxacin
Number of subjects: 80
Study: 15840746

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene citrate (150 mg for 5 days from the third day of a progesterone withdrawal bleeding)
Number of subjects: 100
Study: 12477504

Group type: EXPERIMENTAL
Intervention: IV albumin treatment for OHSS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal control women
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Women with OHSS before treatment
Number of subjects: 43
Study: 9790269

Group type: EXPERIMENTAL
Intervention: TAP-144SR (long-acting gonadotropin-releasing hormone analog)
Number of subjects: 35
Study: 7621492

Group type: EXPERIMENTAL
Intervention: 0.55 mM CHX plus NaF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.2 mM CHX plus NaF
Number of subjects: 10

Group type: COMPARATOR
Intervention: 12.0 mM NaF
Number of subjects: 10
Study: 2279371

Group type: EXPERIMENTAL
Intervention: Corometrics and Cetro single spiral electrodes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hewlett-Packard double spiral electrode
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Copeland electrodes
Number of subjects: 50
Study: 7412428

Group type: EXPERIMENTAL
Intervention: Flow-sheet summary record (Group S)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard medical record plus flow-sheet summary record (Group C)
Number of subjects: 95
Study: 29239982

Group type: EXPERIMENTAL
Intervention: Traditional Set (TS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paired Set (PS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Superset (SS)
Number of subjects: 13
Study: 28731609

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake (mean Na intake: 4309.6 ± 1344.4 mg/day)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Dietary sodium/potassium (Na/K) ratio
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Urinary sodium/potassium (UNa/UK) ratio
Number of subjects: 796
Study: 25434837

Group type: EXPERIMENTAL
Intervention: FOS group (subjective assessment of force of stream)
Number of subjects: 108

Group type: COMPARATOR
Intervention: SVT group (standard voiding trial)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: FOS group
Number of subjects: 108

Group type: COMPARATOR
Intervention: SVT group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups (FOS and SVT)
Number of subjects: 108
Study: 22762449

Group type: EXPERIMENTAL
Intervention: Telemedicine case management (televideo educator visits, individualized goal-setting/problem solving)
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665
Study: 21292644

Group type: COMPARATOR
Intervention: Pegfilgrastim on day 2
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day 4
Number of subjects: 103
Study: 19627212

Group type: EXPERIMENTAL
Intervention: Honey solution (75 g once daily for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sugar solution (honey-comparable, 75 g once daily for 14 days)
Number of subjects: 60
Study: 17846668

Group type: EXPERIMENTAL
Intervention: ABM/P‐15 'putty' graft group
Number of subjects: 16

Group type: COMPARATOR
Intervention: OFD (Open Flap Debridement)
Number of subjects: 16
Study: 15586631

Group type: EXPERIMENTAL
Intervention: FDG PET in generalized epilepsy
Number of subjects: 22

Group type: COMPARATOR
Intervention: FDG PET in localization related epilepsy
Number of subjects: 22
Study: 11565668

Group type: EXPERIMENTAL
Intervention: Hypocapnia (PaCO2 = 30 to 32 mm Hg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normocapnia (PaCO2 = 40 to 42 mm Hg)
Number of subjects: 61
Study: 9632446

Group type: EXPERIMENTAL
Intervention: Hyperfractionated irradiation plus concurrent chemotherapy (combined treatment)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Hyperfractionated irradiation alone
Number of subjects: 116
Study: 8148291

Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine sulfate 0.25 mg and fentanyl 25 micrograms via CSE technique
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional epidural analgesia
Number of subjects: 59
Study: 3339839

Group type: COMPARATOR
Intervention: HMO
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: free-for-service care
Number of subjects: 244
Study: 31715440

Group type: EXPERIMENTAL
Intervention: Chronic pain status
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Chronic pain prevalence
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Chronic pain and opioid use
Number of subjects: 309
Study: 28697492

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 354
Study: 25130918

Group type: EXPERIMENTAL
Intervention: Copper oxide impregnated socks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control socks (without copper oxide)
Number of subjects: 60
Study: 23222083

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 7

Group type: COMPARATOR
Intervention: Traditional ergometer rowing training
Number of subjects: 7
Study: 20886729

Group type: EXPERIMENTAL
Intervention: Administration of immunomodulators
Number of subjects: 0
Study: 18181711

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15905656

Group type: EXPERIMENTAL
Intervention: Computer-aided dosing of warfarin (n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinician dosing of warfarin (n=16)
Number of subjects: 30
Study: 13129806

Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg daily
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1282
Study: 10741628

Group type: EXPERIMENTAL
Intervention: 50 mg/day oral mibefradil for 8 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg/day oral mibefradil for 8 days
Number of subjects: 10
Study: 9023498

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate 1.8 g
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pethidine 100 mg
Number of subjects: 150
Study: 1353717

Group type: EXPERIMENTAL
Intervention: salbutamol 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: fenoterol 5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: normal saline solution
Number of subjects: 24
Study: 6342295

Group type: EXPERIMENTAL
Intervention: Locally injected orgotein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injection with procaine hydrochloride (control)
Number of subjects: 0
Study: 31771512

Group type: EXPERIMENTAL
Intervention: Deep cervical block (DCB) receiving 20 mL ropivacaine 0.5% (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermediate cervical block (ICB) receiving 20 mL ropivacaine 0.5% (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perivascular infiltration of the internal carotid artery (PVB) receiving 20 mL ropivacaine 0.5% and 10 mL ropivacaine 0.3% (n=10)
Number of subjects: 30
Study: 26801970

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for psychosis (EASY) in adults, collected from 2009 to 2011.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service for psychosis (EASY) in youth, collected in 2010.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (FEP study 1 year before the EI service, 2000) for adults.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (FEP study 1 year before the EI service, 2000) for youth.
Number of subjects: 0
Study: 26362785

Group type: EXPERIMENTAL
Intervention: Preoperative decolonization treatment for S aureus carriers
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Noncarriers (no treatment)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: S aureus carriers
Number of subjects: 1028
Study: 25495568

Group type: EXPERIMENTAL
Intervention: Furosemide and standard-dosed Solifenacin (10 mg per day)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Furosemide and low-dosed Solifenacin (5 mg per day)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Furosemide only (Control group)
Number of subjects: 378
Study: 22521671

Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen (600 mg p.o. 1h before surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Postoperative ibuprofen (placebo after surgery)
Number of subjects: 120
Study: 20141734

Group type: EXPERIMENTAL
Intervention: Scalp penetration acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 70
Study: 17695436

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CF: cisplatin and 5-fluorouracil)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Irinotecan or taxane-based regimens
Number of subjects: 180
Study: 16121218

Group type: EXPERIMENTAL
Intervention: Intensive regimen including mitoxantrone plus cytarabine, two consolidation courses, one with timed-sequential high-dose cytarabine, asparaginase and amsacrine.
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Allogenic bone-marrow transplantation (allo-BMT) from an HLA-identical sibling in CR1.
Number of subjects: 341

Group type: COMPARATOR
Intervention: No maintenance therapy (MT-).
Number of subjects: 341

Group type: COMPARATOR
Intervention: Maintenance therapy (MT).
Number of subjects: 341
Study: 12100914

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 258

Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 258
Study: 10100788

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with best medical therapy
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) for asymptomatic disease
Number of subjects: 634
Study: 7785280

Group type: EXPERIMENTAL
Intervention: 40 mg Volon A
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg Volon A
Number of subjects: 40
Study: 2272190

Group type: EXPERIMENTAL
Intervention: Controlled-release trazodone (150 mg)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard trazodone (150 mg)
Number of subjects: 347
Study: 7418410

Group type: EXPERIMENTAL
Intervention: Lippes loop
Number of subjects: 841

Group type: COMPARATOR
Intervention: Copper 7
Number of subjects: 841

Group type: COMPARATOR
Intervention: Postpartum T
Number of subjects: 841

Group type: COMPARATOR
Intervention: All three devices
Number of subjects: 841
Study: 31368908

Group type: EXPERIMENTAL
Intervention: Etoricoxib (n=32)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Diclofenac (n=32)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 97
Study: 28039869

Group type: EXPERIMENTAL
Intervention: Incremental condition
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Entity condition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 25249191

Group type: EXPERIMENTAL
Intervention: Intervention group (8 sessions before discharge and 4 home visits by trained nurses)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study: 23546553

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 467
Study: 21190404

Group type: EXPERIMENTAL
Intervention: computer-delivered, mother-daughter intervention
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 546
Study: 20031847

Group type: EXPERIMENTAL
Intervention: TEAM Care by trained pharmacists and pharmacy technicians
Number of subjects: 597

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: TEAM Care
Number of subjects: 597
Study: 16192451

Group type: EXPERIMENTAL
Intervention: Iseganan
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 12653747

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 20% 5-aminolaevulinic acid (ALA) applied 4 hours before illumination with 100 J cm‐2 narrowband red light (630 +/- 15 nm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical 5-fluorouracil (5-FU) applied to lesions for 4 weeks, with a repeat treatment cycle after 6 weeks if required
Number of subjects: 40
Study: 11053909

Group type: EXPERIMENTAL
Intervention: Levofloxacin (100 mg t.d.s. orally for 5 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cefazolin sodium (1 g b.i.d. intravenously for 5 days)
Number of subjects: 44
Study: 9198569

Group type: EXPERIMENTAL
Intervention: Tension-free surgical treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Shouldice herniorraphy
Number of subjects: 64
Study: 8410113

Group type: EXPERIMENTAL
Intervention: Leucovorin-modulated 5-FU (LV + 5-FU)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: MOF (lomustine, vincristine, and 5-FU)
Number of subjects: 1081
Study: 3455938

Group type: EXPERIMENTAL
Intervention: 0.2% CH gel
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2% CH solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control site (no irrigation)
Number of subjects: 16
Study: 31106666

Group type: EXPERIMENTAL
Intervention: Tocilizumab without methotrexate (SWITCH)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Tocilizumab with methotrexate (ADD-ON)
Number of subjects: 194
Study: 28639089

Group type: EXPERIMENTAL
Intervention: Korean traditional music (KTM) during surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: No Korean traditional music (control) during surgery
Number of subjects: 52
Study: 26940720

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 25045152

Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as a genistein tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as a genistein tablet in low fat milk
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg genistein provided as soy milk containing genistein glycosides
Number of subjects: 12
Study: 22533447

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate (7·5‐15 mg weekly)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 478
Study: 20809062

Group type: EXPERIMENTAL
Intervention: Shaping exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: General activity training
Number of subjects: 30